Circulating Biomarkers for Management of Cancer Therapeutics-related Cardiac Dysfunction

Overview

Journal Cardiovasc Res

Specialty Cardiology & Vascular Diseases

Date 2022 May 31

PMID 35640873

Authors

Claire Tonry

Adam Russell-Hallinan

Claire McCune

Patrick Collier

Mark Harbinson

Lana Dixon

Chris J Watson

Affiliations

Soon will be listed here.

Abstract

Cancer therapeutics-related cardiac dysfunction (CTRCD) has emerged as a major cause of morbidity and mortality in cancer survivors. Effective clinical management of CTRCD is impeded by a lack of sensitive diagnostic and prognostic strategies. Circulating molecular markers could potentially address this need as they are often indicative of cardiac stress before cardiac damage can be detected clinically. A growing understanding of the underlying physiological mechanisms for CTRCD has inspired research efforts to identify novel pathophysiologically relevant biomarkers that may also guide development of cardio-protective therapeutic approaches. The purpose of this review is to evaluate current circulating biomarkers of cardiac stress and their potential role in diagnosis and management of CTRCD. We also discuss some emerging avenues for CTRCD-focused biomarker investigations.

Citing Articles

Discovery of plasma proteins and metabolites associated with left ventricular cardiac dysfunction in pan-cancer patients.

Lal J, Fang M, Hussain M, Abraham A, Tonegawa-Kuji R, Hou Y Cardiooncology. 2025; 11(1):17.

PMID: 39948601 PMC: 11823021. DOI: 10.1186/s40959-025-00309-6.

A longitudinal evaluation of oxidative stress - mitochondrial dysfunction - ferroptosis genes in anthracycline-induced cardiotoxicity.

Qianqian R, Peng Z, Licai Z, Ruizhi Z, Tianhe Y, Xiangwen X BMC Cardiovasc Disord. 2024; 24(1):350.

PMID: 38987722 PMC: 11234563. DOI: 10.1186/s12872-024-03967-z.

Exercise, cancer, and the cardiovascular system: clinical effects and mechanistic insights.

Wernhart S, Rassaf T Basic Res Cardiol. 2024; 120(1):35-55.

PMID: 38353711 PMC: 11790717. DOI: 10.1007/s00395-024-01034-4.

Risk and Management of Patients with Cancer and Heart Disease.

Hill L, Delgado B, Lambrinou E, Mannion T, Harbinson M, McCune C Cardiol Ther. 2023; 12(2):227-241.

PMID: 36757637 PMC: 10209380. DOI: 10.1007/s40119-023-00305-w.

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study.

Zhang C, Chen Z, Qin S, Zhu Y, Shu L, Zuo Z Front Cardiovasc Med. 2023; 10:1052699.

PMID: 36755798 PMC: 9899928. DOI: 10.3389/fcvm.2023.1052699.

References

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E . Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. J Pharmacol Exp Ther. 2018; 366(1):158-168. DOI: 10.1124/jpet.118.249235. View

Qiao F, Fang J, Xu J, Zhao W, Ni Y, Akuo B . The role of adrenomedullin in the pathogenesis of gastric cancer. Oncotarget. 2017; 8(51):88464-88474. PMC: 5687619. DOI: 10.18632/oncotarget.18881. View

Jespersen M, Fano S, Stenor C, Moller A . A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021; 5(11):ytab342. PMC: 8637790. DOI: 10.1093/ehjcr/ytab342. View

Santoro C, Arpino G, Esposito R, Lembo M, Paciolla I, Cardalesi C . 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. Eur Heart J Cardiovasc Imaging. 2017; 18(8):930-936. DOI: 10.1093/ehjci/jex033. View

Boulanger C, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A . Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation. 2001; 104(22):2649-52. DOI: 10.1161/hc4701.100516. View

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

Wang H, Sheehan R, Palmer A, Everley R, Boswell S, Ron-Harel N . Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell Syst. 2019; 8(5):412-426.e7. PMC: 6657491. DOI: 10.1016/j.cels.2019.03.009. View

Fradley M, Beckie T, Brown S, Cheng R, Dent S, Nohria A . Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association. Circulation. 2021; 144(3):e41-e55. PMC: 8992663. DOI: 10.1161/CIR.0000000000000986. View

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

10.

Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K . Plasma brain natriuretic peptide levels are elevated in patients with cancer. PLoS One. 2017; 12(6):e0178607. PMC: 5453551. DOI: 10.1371/journal.pone.0178607. View

11.

Weinberg E, Shimpo M, Hurwitz S, Tominaga S, Rouleau J, Lee R . Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003; 107(5):721-6. DOI: 10.1161/01.cir.0000047274.66749.fe. View

12.

Thum T, Condorelli G . Long noncoding RNAs and microRNAs in cardiovascular pathophysiology. Circ Res. 2015; 116(4):751-62. DOI: 10.1161/CIRCRESAHA.116.303549. View

13.

Florido R, Smith K, Cuomo K, Russell S . Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc. 2017; 6(9). PMC: 5634312. DOI: 10.1161/JAHA.117.006915. View

14.

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

15.

Upshaw J, Finkelman B, Hubbard R, Smith A, Narayan H, Arndt L . Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy. JACC Cardiovasc Imaging. 2019; 13(1 Pt 2):198-210. PMC: 7236624. DOI: 10.1016/j.jcmg.2019.07.018. View

16.

Putt M, Hahn V, Januzzi J, Sawaya H, Sebag I, Plana J . Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015; 61(9):1164-72. PMC: 4667170. DOI: 10.1373/clinchem.2015.241232. View

17.

Tonry C, McDonald K, Ledwidge M, Hernandez B, Glezeva N, Rooney C . Multiplexed measurement of candidate blood protein biomarkers of heart failure. ESC Heart Fail. 2021; 8(3):2248-2258. PMC: 8120401. DOI: 10.1002/ehf2.13320. View

18.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

19.

Vacchi-Suzzi C, Bauer Y, Berridge B, Bongiovanni S, Gerrish K, Hamadeh H . Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One. 2012; 7(7):e40395. PMC: 3409211. DOI: 10.1371/journal.pone.0040395. View

20.

Levick S, Soto-Pantoja D, Bi J, Hundley W, Widiapradja A, Manteufel E . Doxorubicin-Induced Myocardial Fibrosis Involves the Neurokinin-1 Receptor and Direct Effects on Cardiac Fibroblasts. Heart Lung Circ. 2018; 28(10):1598-1605. PMC: 7901001. DOI: 10.1016/j.hlc.2018.08.003. View